医药行业文章摘要标题梳理：2023年ASCO本土创新药进展跟踪-230503（25页）.pdf

1、丁丹（分析师）邮箱：电话：0755-23976735证书编号：S0880514030001黄炎（分析师）电话：021-38675923证书编号：S088052107000122023年ASCO本土创新药进展跟踪0102ASCO(ASCO)2023 ASCO2023.6.2-2023.6.6ASCO2022ASCODESTINY-Breast04EnhertuHer2ADCHK2021.4.1-2021.6.3031%2022.5.13-2022.7.638%2023 ASCO4ASCOOralPoster DisscusionPosterPblication OnlyBDASCOVXfWsWl

2、YjZnPtRrM8ObPbRsQnNoMsRiNrRnQeRpPsPaQrRuMNZmPqOxNmOqQ32023年ASCO本土创新药进展跟踪2023 ASCOHER2CDK4/6Publication OnlyNeoadjuvant pyrotinib plus trastuzumab,dalpiciclib,and letrozole for triple-positive breast cancer:A pilot trial.Pilot Trial+https:/meetings.asco.org/abstracts-presentations/224842Publication O

3、nlyPreliminary analysis of pyrotiniband dalpiciclib-based therapy in HER2-positive advanced breast cancer(ABC).HER2https:/meetings.asco.org/abstracts-presentations/222842Poster SessionUpdated results from a phase 2 study on dalpiciclib and pyrotinib,a dual-oral chemotherapy-free regimen in HER2-posi

4、tive advanced breast cancer(DAP-HER-01).IIHER2(DAP-HER-01)https:/meetings.asco.org/abstracts-presentations/222583Poster SessionPLEASURABLE:Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotiniband endocrine therapy(ET)in women with dual-receptor positive(ER+/H

5、ER2+)metastatic breast cancer(MBC).PLEASURABLE(II)ER+/HER2+https:/meetings.asco.org/abstracts-presentations/222584CDK4/6Publication OnlyNeoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive,HER2-negative breast cancer.HR+/HER2-https:/meetings.asco.o

6、rg/abstracts-presentations/2248432023 ASCOPD(L)142023年ASCO本土创新药进展跟踪2023 ASCOPD(L)1SHR-1701PD-L1/TGF-Poster SessionSHR-1701 in combination with platinum-based chemotherapy and BP102(a bevacizumab biosimilar)for persistent,recurrent,or metastatic cervical cancer:Data from a phase 1b/3 study.SHR-1701BP